CTRI/2020/10/028602进行中（未招募）2 期
A Multicentre, Phase 2, Randomised Study to Assess the Efficacy and Safety of Bemcentinib for the Treatment of COVID-19 in Hospitalised Patients
试验速览
- 阶段
- 2 期
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1.Adults (ââ?°Â¥18 years) with SARS-CoV-2 infection confirmed by laboratory tests and/or point of care tests (which may include results from a test that was performed prior to hospital admission if, in the opinion of theInvestigator, it is relevant to ongoing COVID 19).
- •2.Patients with symptoms and/or signs consistent with COVID-19, requiring treatment.
- •3.A score of Grade 3 to 5 on the 9-point ordinal scale.In India; only patients with a score of Grade 4 or 5 will be enrolled.
- •4.a) Male patients:
- •Ã¢â?¬Â¢A male patient must agree to use contraception as detailed in Appendix 5 during the treatment period and for at least 120 days after the last dose of study treatment and refrain from donating sperm during this period.
- •b) Female patients:
- •Ã¢â?¬Â¢A female patient is eligible to participate if she is not pregnant, not breastfeeding, and at least 1 of the following conditions applies:
- •i Not a woman of childbearing potential
- •iiA woman of childbearing potential who agrees to follow the contraceptive guidance in Appendix 5 during the treatment period and for at least 120 days after the last dose of study treatment.
- •5.Women who are lactating who agree not to breastfeed their child during the study and for at least 120 days after termination of study therapy (they may continue to express milk away from the child during this period, but this milk must be discarded).
- •6.Ability to provide informed consent signed by the study patient or legally authorised representative.
排除标准
- •1.Patients who have previously had a score of 6 or 7 on the 9-point ordinal scale.
- •2.Inability to swallow capsules (administration via nasogastric tube is permitted in patients who become unable to swallow after starting the study drug)
- •3.History of the following cardiac conditions:
- •a)Myocardial infarction within 3 months prior to the first dose
- •b)Unstable angina
- •c)History of clinically significant dysrhythmias (long QT features on ECG, sustained bradycardia [ââ?°Â¤55 bpm]), left bundle branch block, or ventricular arrhythmia) or history of familial long QT.Patients with an implantable cardioverter defibrillator device in place, will be allowed to enrol. Atrial fibrillation will not be a reason for exclusion.
- •4.Screening 12-lead ECG with a measurable QT interval according to Fridericia correction (QTcF) >470 msec. In the presence of a cardiac pacemaker, QTcF will need to be calculated from an ECG which has been recorded during a period where ventricular (QRS) complexes without pacing are present. If no unpaced ventricular complexes are present to allow calculation of QTcF, the patient should not be enrolled in this protocol
- •5.Clinically significant hypokalaemia: Individuals who do not meet this criterion may be rescreened once, after correction of 6.Therapeutic anticoagulation with vitamin K antagonists. Note: Patients receiving low doses prescribed to maintain the patency of venous access devices may be included.
- •7.Previous bowel resection that would interfere with drug absorption.
- •8.Any patient whose interests are not best served by study participation, as determined by a senior attending clinician.
- •9.Alanine aminotransferase/aspartate aminotransferase >5 Ã?â?? the upper limit of normal electrolyte abnormality.
- •10.Current treatment (or planned initiation of treatment during the first 15 days of the study) for human immunodeficiency virus (HIV) or tuberculosis (TB).
- •11.Positive serologic assay at screening for hepatitis B virus (Hep B surface antigen) or hepatitis C virus (hepatitis C PCR or hepatitis C core antigen) at local laboratory.
- •12.Stage 4 severe chronic kidney disease.
- •13.Anticipated transfer to another hospital that is not a study centre within 72 hours.
- •14.Allergy to any study treatment.
- •15.Experimental off-label usage of medicinal products as treatments for COVID-19 (except where the product has either been given a positive opinion under the Early Access to Medicines Scheme [EAMS] or is a SARS-CoV-2 vaccine) at the time of enrolment.
- •16.Patients participating in another clinical study of an investigational medicinal product.
- •17.Current or planned treatment for tuberculosis.
研究者
相似试验
进行中（未招募）
1 期
A Phase II, Randomised, Multi-Centre Study Evaluating Lapatinib in Combination with Vinorelbine or Capecitabine in Women with ErbB2 Overexpressing Metastatic Breast CancerBreast Cancer (with ErbB2 Overexpressing Metastatic Breast Cancer)MedDRA version: 9.1Level: LLTClassification code 10027475Term: Metastatic breast cancerEUCTR2009-009885-15-FRGlaxoSmithKline Research & Development Ltd105
进行中（未招募）
不适用
A study to determine the safety and efficacy of Laptinib in combination with Vinorelbine or Capecitabine in Women with ErbB2-Overexpressing Metastatic Breast Cancer.Breast Cancer (with ErbB2 Overexpressing Metastatic Breast Cancer)MedDRA version: 18.0Level: LLTClassification code 10027475Term: Metastatic breast cancerSystem Organ Class: 100000004864EUCTR2009-009885-15-BGGlaxoSmithKline Research & Development Ltd105
进行中（未招募）
1 期
A Phase II, Randomised, Multi-Centre Study Evaluating Lapatinib in Combination with Vinorelbine or Capecitabine in Women with ErbB2 Overexpressing Metastatic Breast CancerBreast Cancer (with ErbB2 Overexpressing Metastatic Breast Cancer)MedDRA version: 9.1Level: LLTClassification code 10027475Term: Metastatic breast cancerEUCTR2009-009885-15-GRGlaxoSmithKline Research & Development Ltd105
进行中（未招募）
1 期
A Phase II, Randomised, Multi-Centre Study Evaluating Lapatinib in Combination with Vinorelbine or Capecitabine in Women with ErbB2 Overexpressing Metastatic Breast Cancer - LAP112620_VITAwomen with ErbB2 overexpressing metastatic breast cancer who have received no more than one chemotherapeutic regimen in the metastatic setting.MedDRA version: 9.1Level: LLTClassification code 10027475EUCTR2009-009885-15-ITGlaxoSmithKline Research & Development Ltd105
进行中（未招募）
1 期
A Phase II, Randomised, Multi-Centre Study Evaluating Lapatinib in Combination with Vinorelbine or Capecitabine in Women with ErbB2 Overexpressing Metastatic Breast CancerEUCTR2009-009885-15-DEGlaxoSmithKline Research & Development Ltd105